|
15 Jul 2025 |
Balaji Amines
|
Consensus Share Price Target
|
1760.10 |
1971.50 |
- |
12.01 |
buy
|
|
|
|
|
26 Mar 2024
|
Balaji Amines
|
Prabhudas Lilladhar
|
1760.10
|
|
2051.95
(-14.22%)
|
|
Not Rated
|
|
|
|
|
20 Mar 2024
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
2653.00
|
2036.70
(-13.58%)
|
|
Buy
|
|
|
|
|
30 May 2023
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
3364.00
|
2121.25
(-17.03%)
|
|
Buy
|
|
|
|
|
23 May 2023
|
Balaji Amines
|
Edelweiss
|
1760.10
|
3090.00
|
2211.10
(-20.40%)
|
|
Buy
|
|
|
Dismal operating performance
|
|
31 Oct 2022
|
Balaji Amines
|
Edelweiss
|
1760.10
|
4250.00
|
3025.00
(-41.81%)
|
|
Buy
|
|
|
Strong capex led volume surge to drive long-term growth, Maintain BUY
|
|
07 Sep 2022
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
4542.00
|
3618.10
(-51.35%)
|
|
Buy
|
|
|
|
|
14 May 2022
|
Balaji Amines
|
Edelweiss
|
1760.10
|
4150.00
|
2974.20
(-40.82%)
|
|
Buy
|
|
|
Record quarter led by volume and realisations, Reiterate BUY
|
|
29 Mar 2022
|
Balaji Amines
|
Edelweiss
|
1760.10
|
4150.00
|
2859.85
(-38.45%)
|
|
Buy
|
|
|
Plant Visit Note
|
|
28 Feb 2022
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
3916.00
|
2820.05
(-37.59%)
|
|
Buy
|
|
|
Despite overall consolidated sales volume witnessing a decline of 13.8% to 27,589 mt in Q3FY22, Balaji Amines' revenue from operations grew by a pleasing 44.1% to Rs. 564.90 crs as against Rs. 392.13 crs in the corresponding period in the prior year. The demand for certain products from pharmaceutical clients remained suppressed on account of...
|
|
09 Feb 2022
|
Balaji Amines
|
Edelweiss
|
1760.10
|
4150.00
|
3120.45
(-43.59%)
|
|
Buy
|
|
|
Better utilisation and mix to drive medium term earnings
|
|
29 Oct 2021
|
Balaji Amines
|
Edelweiss
|
1760.10
|
4000.00
|
3459.90
(-49.13%)
|
|
Buy
|
|
|
Balaji Amines Ltd (BAL) witnessed strong top-line growth across standalone Amines business and subsidiary Balaji Specialty Chemicals (BSC).
|
|
28 Jun 2021
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
3613.00
|
2670.25
(-34.08%)
|
Target met |
Buy
|
|
|
oxygen and logistical issues. Total Q4 sales volume stood at 24,878 mt, a 12.3% decline on a quarter-on-quarter quarter basis. Of this specialty chemicals...
|
|
27 May 2021
|
Balaji Amines
|
Edelweiss
|
1760.10
|
3197.00
|
2846.55
(-38.17%)
|
Target met |
Buy
|
|
|
Stellar quarter; new capacities to drive growth in FY22
|
|
11 Feb 2021
|
Balaji Amines
|
Edelweiss
|
1760.10
|
1678.00
|
1639.45
(7.36%)
|
Target met |
Buy
|
|
|
Balaji Amines (BAL) posted record high results in Q3FY21 consolidated revenue grew 72% YoY/39% QoQ to INR392cr (v/s est. 37% growth).
|
|
04 Nov 2020
|
Balaji Amines
|
Edelweiss
|
1760.10
|
950.00
|
843.40
(108.69%)
|
Target met |
Buy
|
|
|
Balaji Amines Ltd's (BAL) Q2FY21 consolidated revenue was at a record INR 282 crore, up 24% YoY/27% QoQ, and was 13% ahead of our estimates.
|
|
31 Aug 2020
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
1104.00
|
838.75
(109.85%)
|
Target met |
Buy
|
|
|
Sub optimal capacity utilization in April and May operating at 70% and 80% respectively, due to Covid hampered volumes in the first quarter this fiscal which plummeted almost 18% sequentially on an absolute basis,...
|
|
16 Aug 2020
|
Balaji Amines
|
Edelweiss
|
1760.10
|
825.00
|
824.70
(113.42%)
|
Target met |
Buy
|
|
|
Balaji Amines' (BAL) margin expanded in Q1FY21 on the back of a favourable product mix and benign raw material environment.
|
|
28 Feb 2020
|
Balaji Amines
|
CD Equisearch
|
1760.10
|
543.00
|
402.75
(337.02%)
|
Target met |
Buy
|
|
|
BAL started manufacturing acetonitrile from November with an installed capacity of 9000 tons. The domestic demand for acetonitrile is around 12000 tons annually. BAL is currently manufacturing ~3000 tons of...
|
|
06 Feb 2020
|
Balaji Amines
|
Edelweiss
|
1760.10
|
500.00
|
411.85
(327.36%)
|
Target met |
Buy
|
|
|
Balaji Amines Ltd's (BAL) Q3FY20 results were broadly in-line with our expectations.
|
|
20 Jan 2020
|
Balaji Amines
|
HDFC Securities
|
1760.10
|
490.00
|
470.05
(274.45%)
|
Target met |
Buy
|
|
|
Given the (1) Uncertainty in the ramp up of BSCPL (2) Muted earnings growth prospect (3) Declining return ratios (ROE: 16.1/15.1/13.5%, RoIC: 22.5/21.7/18.8% in FY20E/21E/22E), we prefer Alkyl Amines over Balaji in the Amines space. Maintain BUY with a TP of Rs 490 (13x Dec-21E EPS). We visited Balaji Amines and its subsidiarys Solapur facility, which was followed by an interaction with Mr. Ram Reddy, the companys Managing Director.
|